Myopia

How Extended Screen Time Can Affect Your Child's Vision and Ways to Encourage a "Screen Staycation" this Summer

Retrieved on: 
Thursday, August 11, 2022
Cooking, Broadway, Lens (anatomy), POP, SO, Research, Doctorate, MTV, Sun, Screen time, Education, Tampa Bay Times, Sun Fun Festival, BABY, American Optometric Association, News, Illinois College, Disease, Hairspray (1988 film), REAL, Risk, Illinois College of Optometry, Applegate, Tech, Hasbro, HOPE, American Academy of Optometry, FAMILY, Bay News 9, Publication, Duff, Awareness, ELLE, THE, Science fiction, COVD, Fox 13, Myopia, Clarins, Television, American Academy, College of Optometrists, COVID-19, Hallmark, Netflix, Parent, Social media, College of Optometrists in Vision Development, Hallmark Channel, HOME, Time, Video, Bay, Toy, Optometry, Child

ST. LOUIS, Aug. 10, 2022 /PRNewswire/ --

Key Points: 
  • That's why we're encouraging families to spend more time outdoors this summer and take a "Screen Staycation" a challenge to go 24 hours without any screens.
  • Myopia can now be managed, and early intervention is key to setting children up for success today and in the future.
  • She received her first major role in a feature film when she was cast as 'Summer Wheatley' in NAPOLEON DYNAMITE.
  • Additionally, he is Past President of the Hillsborough Society of Optometry and is chair of the Children's Vision Committee of the Florida Optometric Association.

Eyenovia Reports Second Quarter 2022 Financial Results

Retrieved on: 
Wednesday, August 10, 2022
FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Manufacturing & Service Operations Management, Phenylephrine, Reflex, Electronics, Presbyopia, U.S. Securities and Exchange Commission, Running, NDA, Forward-looking statement, GLOBE, Senior, CA, Technology, Visual acuity, Microcline, Board, Director, Annual report, ET, Compliance, Pilocarpine, Myopia, Pupil, Mydriasis, Marketing, COVID-19, Company, Eye, Therapy, MAP, Research, New Drug Application, Ophthalmology, Time, Food, Efficiency, Management, Medical device, Pharmaceutical industry, Video game, Telescopic sight

NEW YORK, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced its financial and operating results for the second quarter ended June 30, 2022.

Key Points: 
  • Total license revenue was $0.0 million for the second quarter of 2022 as compared to $2.0 million for the second quarter of 2021.
  • Research and development expenses totaled approximately $3.6 million for the second quarter of 2022 as compared to $3.7 million for the second quarter of 2021, a decrease of approximately (2.7%).
  • For the second quarter of 2022, general and administrative expenses were approximately $3.5 million, compared to $2.3 million for the second quarter of 2021, an increase of approximately 53.8%.
  • Total operating expenses for the second quarter of 2022 were approximately $7.1 million compared to $6.0 million for the second quarter of 2021.

STAAR Surgical and Joe Jonas Team Up to Introduce New Life-Changing EVO ICL to Millions of Americans Suffering from Distance Vision Problems

Retrieved on: 
Wednesday, August 10, 2022
Other Consumer, Women, Parenting, Men, Pharmaceutical, Optical, TV and Radio, Family, Music, Medical Devices, Consumer, LGBTQ+, Entertainment, Film & Motion Pictures, Surgery, Health, Advertising, Communications, Celebrity, U.S. Securities and Exchange Commission, Lens (anatomy), CEO, Dioptre, Dry eye syndrome, Prevalence, Security (finance), Marketing, Education, STAAR, Ophthalmology, Night vision, Marriage, MD, Jonas, Iris, Glaucoma, Astigmatism, Multimedia, Lens, Retinal implant, EVO, American Society of Cataract and Refractive Surgery, Inflammation, Technology, Perseverance, Partnership, Refractive surgery, Cornea, Literature, Myopia, Intraocular lens, ICL, Awareness, Nave, Social media, Goal, FDA, Quality, Cataract, Hans Hassle, Society, Review, Eye, Glasses, NASDAQ, Intention, Vision disorder, Nursing, ASCRS, Telescopic sight, Medical device, Borosilicate glass, Life, LASIK, Patient

Joe Jonas had myopia since childhood, which is also known as nearsightedness or the need for distance vision correction.

Key Points: 
  • Joe Jonas had myopia since childhood, which is also known as nearsightedness or the need for distance vision correction.
  • He decided to undergo the EVO procedure, which involved adding a small, flexible lens in both eyes to correct his distance vision.
  • Joe Jonas was a great candidate for EVO and we are thrilled to have helped him achieve his vision goals.
  • Joe Jonas needed EVO lenses below -5.0 diopters, so he was a great candidate for EVO, said Scott D. Barnes, MD, Chief Medical Officer of STAAR Surgical.

Eyenovia to Report Second Quarter 2022 Results on Wednesday, August 10

Retrieved on: 
Thursday, August 4, 2022
GLOBE, Presbyopia, MAP, Myopia, Company, Review, NASDAQ, Therapy, Mydriasis, Pharmaceutical industry

NEW YORK, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP) therapeutics, announced that the Company will release financial results for the second quarter ended June 30, 2022 on Wednesday, August 10, 2022, after the markets close.

Key Points: 
  • NEW YORK, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP) therapeutics, announced that the Company will release financial results for the second quarter ended June 30, 2022 on Wednesday, August 10, 2022, after the markets close.
  • Following the release, Eyenovia management will host a conference call to review the financial and operating results.
  • The conference call is scheduled to begin at 4:30pm ET on Wednesday, August 10, 2022.
  • A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.eyenovia.com .

Zhaoke Ophthalmology Completed Patient Enrollments for the Phase III Clinical Trials of the Myopia Progression Treatment Drug NVK002

Retrieved on: 
Wednesday, August 3, 2022
World, Motherboard, Atropine, Ageing, State Council, Parent, Eye, Safety, Episode I, Sun, Ministry, Director, Company, Fudan University, S. D. Warren Co. v. Maine Board of Environmental Protection, Eye and ENT Hospital of Fudan University, Control, Research, World Health Organization, Technology, US Foods, Growth, List of education ministries, Education, Business, Adolescence, Food, SEHK, CEO, Board, Ophthalmology, Achievement, FDA, Benjamin, National Health Planning and Resources Development Act, Cover My Eyes (Pain and Heaven), Approximation error, Beijing Tongren Hospital, NDA, CIC, The Company, Hospital, Principal, Hong Kong Stock Exchange, Patient, Overalls, Pharmaceutical industry, Vaccine, Medical imaging, Myopia

The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.

Key Points: 
  • The primary objective of the China CHAMP and Mini-CHAMP trials is to evaluate the efficacy and safety of NVK002 for the treatment of myopia progression in children and adolescents.
  • These early completions of patient recruitment across both trials, gives the company a strong headstart in moving towards its goal to lead the market in launching a myopia progression treatment drug.
  • Following this, a New Drug Application ("NDA") submission to the US Food and Drug Administration (the "FDA") is expected in 2023.
  • Dr. Li Xiaoyi (Benjamin), Chairman of the Board of Directors, Executive Director and CEO of Zhaoke Ophthalmology, said, "The early completion of the patient recruitment of NVK002's Phase III clinical trials marks another huge and exciting milestone for Zhaoke Ophthalmology.

Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member

Retrieved on: 
Wednesday, July 27, 2022
CA, Strategic planning, Allergan, Corporation, GLOBE, Intelligence, Bausch & Lomb, U.S. Securities and Exchange Commission, Forward-looking statement, Myopia, NDA, Marketing, Bayer, Board, COVID-19, NASDAQ, Pfizer, Mydriasis, Technology, Company, Patient, Presbyopia, Therapy, Pharmaceutical industry, Management, DRS

NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP) therapeutics, today announced the appointment of current Chief Operating Officer Michael Rowe as the Companys new Chief Executive Officer, effective August 1, 2022.

Key Points: 
  • NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP) therapeutics, today announced the appointment of current Chief Operating Officer Michael Rowe as the Companys new Chief Executive Officer, effective August 1, 2022.
  • Mr. Rowe has also been appointed to Eyenovias Board of Directors, increasing the Board to nine seats following recent appointments of Drs.
  • Eyenovias current Chief Executive Officer, Dr. Sean Ianchulev, previously announced that he will be transitioning to Chairman of the companys Board.
  • For the past four years, we have benefited from Michaels diverse ophthalmic industry experience, and we believe he is the ideal candidate to shepherd Eyenovia through this exciting new chapter in the Companys evolution, stated Dr. Sean Ianchulev, Eyenovias Chief Executive Officer and Chief Medical Officer.

Leading Asian AR startup Rokid Expands into the North American Market

Retrieved on: 
Friday, July 22, 2022
Entertainment, Consumer Electronics, Other Entertainment, Technology, General Entertainment, Other Technology, Electronic Games, Algorithm, Investment, Lens (anatomy), GMV, Industry, VCS, G, Myopia, Xbox, Marketing, Computer, Multimedia, Amazon (company), End, PlayStation, Kickstarter, Light, Bacon roll, AR, Online shopping, Tmall, Pacific Ocean, Zooma, Amazon

Leading AR company Rokid has taken advantage of Amazon Prime Day deals to sell its consumer-grade AR glasses, the Rokid Air resulting in a push into the North American market.

Key Points: 
  • Leading AR company Rokid has taken advantage of Amazon Prime Day deals to sell its consumer-grade AR glasses, the Rokid Air resulting in a push into the North American market.
  • With the Prime Day event over, Rokid is aiming to promote their Rokid Air to a wider range of consumers.
  • View the full release here: https://www.businesswire.com/news/home/20220722005185/en/
    The Rokid Air are the first pair of consumer-grade AR devices launched by Rokid under $500.
  • The outstanding sales figures during Amazon Prime Day is an important milestone in the companys expansion into the North American market.

Hoot and Haag-Streit Announce Partnership to Modernize Education of Progressive Myopia in Kids

Retrieved on: 
Wednesday, July 20, 2022
Eye, Education, VP, ECP, Parent, Myopia, OH, Multimedia, Technology, Patient, Hoot, Automation, Child, Toy

PRINCETON, N.J., July 20, 2022 /PRNewswire/ -- Hoot Myopia Care.com (owned by Hoot Health, Inc.), a digital marketing automation platform for eye doctors practicing myopia management, announced that Haag-Streit, a leader in developing medical devices in the field of eye care, will partner with Hoot to deliver specific programs for ECPs to diagnose, educate and demonstrate myopia management and monitoring in kids.

Key Points: 
  • PRINCETON, N.J., July 20, 2022 /PRNewswire/ -- Hoot Myopia Care.com (owned by Hoot Health, Inc.), a digital marketing automation platform for eye doctors practicing myopia management, announced that Haag-Streit, a leader in developing medical devices in the field of eye care, will partner with Hoot to deliver specific programs for ECPs to diagnose, educate and demonstrate myopia management and monitoring in kids.
  • Haag-Streit will work with Hoot to co-produce educational digital content and myopia specific workflows and integrate it into the Hoot ecosystem.
  • ", said Dr. Shefali Miglani, Chief Medical Officer of Hoot Myopia Care.com.
  • Learn more: https://www.haag-streit.com/haag-streit-usa/
    Hoot is a marketing automation platform for eye care professionals to help them grow and scale their myopia management practice.

Eyenovia Provides Manufacturing Update and Announces Appointment of Bren Kern as SVP of Manufacturing and Operations

Retrieved on: 
Monday, July 18, 2022
Research, Â, Manufacturing & Service Operations Management, U.S. Securities and Exchange Commission, Solution, Therapy, Engineering, GLOBE, Forward-looking statement, Presbyopia, Technology, Insurance, Marketing, NASDAQ, Organization, Silicon, COVID-19, Microcline, Company, CGMP, PMA, CA, Senior, Bausch & Lomb, Myopia, Mydriasis, Pharmaceutical industry, Management, Medical device

With our Redwood City facility now operational, Eyenovia has internal manufacturing capabilities to complement our existing contract manufacturing partners, stated Michael Rowe, Chief Operating Officer of Eyenovia.

Key Points: 
  • With our Redwood City facility now operational, Eyenovia has internal manufacturing capabilities to complement our existing contract manufacturing partners, stated Michael Rowe, Chief Operating Officer of Eyenovia.
  • Eyenovia also announced today the appointment of Bren Kern as the Companys new Senior Vice President of Manufacturing and Operations.
  • I look forward to contributing to the team and championing our internal manufacturing and engineering operations to help bring these exciting solutions to market.
  • Mr. Kern has spent his career helping companies transition from research and development entities into scaled commercial manufacturing organizations.

Global Ophthalmic Devices Market (2022 to 2027) - Growth, Trends, COVID-19 Impact and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, July 15, 2022
Optical, Health, Surgery, Medical Devices, Research report, Eye, World Health Organization, Severe cognitive impairment, Patient, WHO, Vance DeGeneres, CAGR, Review, Astigmatism, Presbyopia, Far-sightedness, Diabetic retinopathy, Ophthalmology, Amblyopia, Approximation error, Eastern, Cataract, COVID-19, Strabismus, Growth, Prevalence, Visual impairment, Myopia, Glaucoma, Pharmaceutical industry, Liquor

The Vision Correction Devices or corrective lenses are used to aid and improve vision for those with common refractive errors like myopia, hypermetropia, astigmatism, and presbyopia.

Key Points: 
  • The Vision Correction Devices or corrective lenses are used to aid and improve vision for those with common refractive errors like myopia, hypermetropia, astigmatism, and presbyopia.
  • Thousands of ophthalmic clinical consultations and operations have been cancelled as a result of the recent pandemic lockdown, potentially causing lasting and substantial eyesight damage to patients.
  • Furthermore, according to a research article titled "The impact of COVID-19 pandemic on ophthalmology services: are we ready for the aftermath?"
  • Hence, the high number of cases is likely to create demand for advanced products and services, thereby boosting the market growth.